Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2160348

Cc1cccc(N)c1C.O=C(O)C(F)(F)F

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.46
TSHR P16473 1/20 0.46
PIK3CA P42336 1/20 0.46
ESR1 P03372 1/20 0.46
KCNH2 Q12809 1/20 0.46
TRPA1 O75762 2/20 0.42
CD44 P16070 1/20 0.42
ATM Q13315 1/20 0.42
ALDH1A1 P00352 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
MYC P01106 1/20 0.37
MEN1 O00255 1/20 0.37
AKR1B10 O60218 1/20 0.37
ABCB11 O95342 1/20 0.37
DHFR P00374 1/20 0.37
LMNA P02545 1/20 0.37
MPO P05164 1/20 0.37
CYP1A2 P05177 1/20 0.37
CHRM1 P11229 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pivalate SCHEMBL28211871 0.87 CYP3A4 (0.48) CYP3A4TSHRPIK3CAESR1KCNH2
O-Tolylamine SCHEMBL1686216 0.85 TDP1 (0.58) CYP3A4ESR1KCNH2CD44ALDH1A1
Oxalic Acid SCHEMBL11574385 0.84 CYP3A4 (0.54) CYP3A4TSHRPIK3CAESR1KCNH2
Acetic Acid SCHEMBL11035058 0.84 CYP3A4 (0.54) CYP3A4TSHRPIK3CATRPA1CD44
Hydrogen Peroxide SCHEMBL28415811 0.84 CYP3A4 (0.65) CYP3A4TSHRPIK3CATRPA1CD44
Trifluoroacetic Acid SCHEMBL4452739 0.83 TDP1 (0.37) CYP3A4TSHRPIK3CAESR1KCNH2
Benzene SCHEMBL29109286 0.82 CYP3A4 (0.68) CYP3A4TSHRPIK3CATRPA1CD44
Trifluoromethanesulfonic Acid SCHEMBL1005216 0.80 TRPA1 (0.45) CYP3A4TSHRPIK3CAESR1KCNH2
SCHEMBL29440219 0.79
SCHEMBL28788726 0.79 CYP3A4 (0.72) CYP3A4TSHRPIK3CATRPA1CD44

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470823-B2 Saturated bicyclic heterocyclic derivatives as SMO antagonists INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) 2013-06-25 US disclosed
US-20110183989-A1 SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS Instituto di Ricerche di Biologia Molecolare P. Ang 2011-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183989-A1 SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS SMO, SHH, GLI1 CYP3A4 3611/4885TSHR 854/4885PIK3CA 1129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.